This is a news story, published by Yahoo, that relates primarily to BioAge Labs news.
For more BioAge Labs news, you can click here:
more BioAge Labs newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
several biotech firms. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest life sciences investment firm Sofinnova Investments news, BioA news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
BioAgeReuters
•82% Informative
BioAge Labs is an obesity therapy-focused startup that has also collaborated with Eli Lilly .
The company's experimental drug, azelaprag, is being developed for the treatment of obesity.
The proposed IPO comes months after BioAge raised $170 million in a funding round led by Sofinnova Investments .
VR Score
93
Informative language
98
Neutral language
81
Article tone
formal
Language
English
Language complexity
63
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links